Halozyme: The Market Is Still Pricing the Old Story While the Cash Flow Says Otherwise

The old story is that Halozyme is a highly leveraged biotech royalty play—$2.15 billion of debt, a tiny equity base, patent lawsuits hanging over its biggest drug. That story still drives how most of the market thinks about this stock.

But the numbers from Q2 2026 don't look like a leveraged biotech anymore. They look like a cash-generating platform that keeps getting more expensive to ignore.

The quarter that changes the frame

Halozyme reported revenue of $481.0 million, up 48% year over year. Royalty revenue—the company's core earnings engine—grew 50% to $307.7 million, driven by continued uptake of Darzalex SC (Janssen's subcutaneous multiple-myeloma drug) and Vyvgart Hytrulo (argenx's neuromuscular therapy). Adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization, a rough proxy for operating cash generation) climbed 46% to $328.8 million. Non-GAAP EPS of $2.28 beat consensus estimates by roughly 25%.

Then management raised every piece of full-year guidance. The midpoint of new 2026 guidance implies roughly $1.87 billion in total revenue, $1.23 billion in royalty revenue, and $1.25 billion in adjusted EBITDA. The adjusted EBITDA number includes approximately $60 million in costs from recent technology acquisitions (Hypercon and Surf Bio), which management framed as investments rather than drag.

What this means is that Halozyme already completed its prior full-year adjusted EBITDA goal by the end of Q2 and has two more quarters to add to it while the bar just moved higher. That is not the operating profile of a company in trouble. That is a platform that found a growth rhythm and is not slowing down.

The cash-flow bridge

The trailing twelve-month free cash flow picture is where the old story really breaks. Halozyme generated $806 million in free cash flow over the TTM period, up 49% year-over-year. Capital expenditures sat at just $12 million—this is a software-like biotech, not a factory business. The FCF margin is 44%, and the operating margin runs at nearly 34%.

Return on invested capital sits at roughly 21%. ROE shows 174%, which is mechanically inflated by aggressive share repurchases shrinking the equity base, but it reflects the underlying truth: the company generates massive cash returns on every dollar of equity left standing.

The market is still pricing the old risk profile. But the cash-flow path already says this is a business printing money, not a biotech praying for approvals.

Why the market hasn't fully moved on

Three things keep investors anchored to the old Halozyme narrative.

First, the balance sheet. Total debt stands at roughly $2.15 billion against $143 million of shareholders' equity, for a debt-to-equity ratio that looks astronomical on paper. The equity number is small because the company has spent years buying back shares with its own cash flow, not because it's insolvent. With $806 million in TTM FCF, the debt is serviceable. Debt finances cheap capital; FCF pays it down. The mechanics are clean.

Second, patent litigation. Halozyme continues to face disputes over its enzyme platform, particularly around Darzalex SC. The company excluded $6.9 million in litigation costs from adjusted EBITDA in Q2, up from $2.6 million a year ago. A July 2026 UK court ruling dismissed MSD's request for further experimental disclosure in a related dispute. The litigation is a real cost, but it has not dented the growth trajectory.

Third, the valuation does not look cheap by traditional measures. The stock trades at roughly 22 times EV/EBITDA and nearly 18 times forward earnings. For a royalty platform growing revenue in the mid-30s to low-40s with FCF margins above 40%, those multiples are not outrageous—but they're not a screaming bargain either. The stock is up 27% year-to-date and has been trending toward its 52-week high of $86. The tape has caught up part of the way.

The partnership engine

What the market may still be underweighting is the pipeline of new royalty sources. Halozyme signed five new collaboration agreements through July 2026, exceeding its full-year goal of three:

• Vertex Pharmaceuticals (April): exclusive Hypercon access for up to three targets
• GSK (May): multiple oncology targets, including the first potential application in antibody-drug conjugates
• Oruka Therapeutics (May): Hypercon for psoriasis/inflammatory targets with mid-single-digit royalties
• Incyte (July): subcutaneous formulation of a monoclonal antibody, with options for two additional targets
• An undisclosed partner licensing the enzyme platform for nucleic acid therapeutics

These won't show up in 2026 or most of 2027. But they represent upfront cash, milestone pathways, and future royalty streams from companies that are not small-cap speculative partners. Vertex and GSK don't sign licensing deals as a hobby.

The setup and the numbers

The financial bridge is straightforward. If Halozyme hits the midpoint of its raised 2026 guidance—roughly $1.25 billion in adjusted EBITDA including the $60 million in new technology investments—and converts that at a rate consistent with the current roughly 80% FCF-to-adjusted-EBITDA ratio, the company generates approximately $1 billion in annual free cash flow. That number only gets bigger in 2027 as Hypercon and Surf Bio begin contributing revenue rather than just adding cost.

Apply a conservative 15x FCF multiple—below the growth the company is actually delivering—to projected 2027 FCF, and the implied enterprise value is roughly $12–13 billion. With $2.15 billion in debt, that implies an equity value of $10–11 billion. On a reduced share count after continued buybacks (the company announced a new $1 billion share buyback authorization and spent $333 million in Q2 alone at an average price of $69), that translates to roughly $110 per share.

The stock trades at roughly $86. The gap between the current price and the FCF-based target is where the inflection lives.

The target, the timeframe, the tripwire

• Target: $110
• Timeframe: 12 months
• Tripwire: A sustained deceleration in royalty revenue growth below 25% year-over-year, or a meaningful guidance cut. If the royalty engine starts losing momentum—whether from patent loss, biosimilar pressure on Darzalex, or partner commercialization failure—the entire thesis hinges on something else picking up the slack. The new partnerships are too early to fill that gap.

I can be wrong again. But the setup is a company that raised guidance after already beating it, generating $800 million-plus in free cash flow, and growing at a rate that makes the debt look like cheap leverage rather than a structural risk. Simple forward multiples on that FCF path beat complex DCF models any day.

The risk mechanics are clean: no options, no leverage, just equity in a business that is converting enzyme science into cash flow faster than the market has adjusted. If the royalty growth stays above the mid-30s and the partnership pipeline holds, this stock gets harder to dismiss with every quarterly report. If it doesn't, you cut it. Discipline over ego.